Efficacy And Safety Of Low-Dose Oral Minoxidil In The Treatment Of Androgenetic Alopecia: A Literature Review

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

In this study, researchers found no evidence of increased prevalence of pericardial effusions in alopecia patients treated with low-dose oral minoxidil compared to those not receiving minoxidil, based on point-of-care ultrasound evaluations.

In this randomized clinical trial, oral minoxidil was not superior to topical minoxidil in increasing hair density in men with androgenetic alopecia over 24 weeks, though photographic analysis suggested oral minoxidil may work better on the vertex area of the scalp.

This review discusses the potential of low-dose oral minoxidil as a safe and effective treatment for certain hair disorders, including alopecia, but reports no new clinical results.

This study found that 1 mg/day low-dose oral minoxidil significantly increased hair count compared to 0.25 mg/day over 24 weeks in women with female pattern hair loss, though no differences were observed in hair-shedding and quality-of-life scores between the two doses.

This study suggests that low-dose oral minoxidil could be a safe and effective option for male and female-patterned hair loss, potentially benefiting those unable to tolerate topical treatments.

In this triple-blind randomized clinical trial, researchers found that oral minoxidil 0.25 mg tablets were as effective as 2% topical minoxidil for increasing hair diameter and density in women with female pattern hair loss, with similarly minor side effects.

This review explains the evolution and current techniques of follicular unit transplantation for hair restoration, identifying conditions suitable for surgery and offering guidelines for dermatologists to assess candidate suitability, focusing on male and female pattern hair loss.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This study reported that oral minoxidil improved hair density and had an acceptable safety profile in women with androgenetic alopecia.

This study reported that low-dose oral minoxidil is generally safe for treating various types of hair loss, though it may cause hypertrichosis and pedal edema, especially at higher doses.

This review discusses the pathophysiology, diagnosis, systemic associations, and treatments for female pattern hair loss and reports no new clinical findings.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

This review article provides an updated overview of the pharmacology, mechanism of action, clinical efficacy, and adverse events associated with topical minoxidil, a widely used treatment for androgenetic alopecia and other hair loss conditions, while noting that its exact mechanism is still not fully understood.

This study evaluated the effectiveness and safety of low-dose oral minoxidil (2.5-5 mg daily) in men with male androgenetic alopecia, aiming to contribute data to an area with limited previous reports. Results are not provided in the abstract.

This study reported that once-daily treatment with oral minoxidil and spironolactone for 12 months reduced hair loss severity and hair shedding in women with pattern hair loss, with generally mild side effects, though results came from an uncontrolled, observational pilot study.

This review discusses various classification systems for male-pattern hair loss, comparing their detail, practicality, and reproducibility, and reports no new clinical outcomes.

This study found that platelet-rich plasma injections significantly increased hair count and density in patients with male pattern hair loss without major side effects, suggesting it may be a safe and effective treatment option.

This study reported that sulfotransferase activity in plucked hair follicles can predict treatment response to 5% topical minoxidil in women with androgenetic alopecia with high sensitivity and specificity.

This study found that altering cell culture conditions to form three-dimensional papilla spheroids can restore the ability of human dermal papilla cells to induce hair growth in adult skin.

This review describes minoxidil's hair regrowth mechanism and discusses dermatological applications, but reports no new clinical results, emphasizing the need for regular use and addressing allergic reactions.

PGD2 stops hair growth and is higher in bald men with AGA.

This study found that androgenetic alopecia may involve a defect in the conversion of hair follicle stem cells to progenitor cells, as demonstrated by a reduced presence of progenitor cells in bald scalp samples.

This study found that Minoxidil had biphasic effects on normal human keratinocytes, stimulating proliferation at micromolar doses, but showing antiproliferative, pro-differentiative, and cytotoxic effects at millimolar concentrations.

This study found that minoxidil stimulates hair follicle growth by promoting dermal papilla cell survival and activating ERK and Akt pathways, which leads to increased proliferation and reduced cell death.

This article reviews the mechanisms by which minoxidil stimulates hair growth and reports no new clinical findings.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

This review discusses the psychological and social impacts of androgenetic alopecia and suggests that medical treatments can have some positive psychological effects, highlighting the condition's moderate stress and impact on body image.

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

This study found that minoxidil significantly increases VEGF mRNA and protein expression in dermal papilla cells, suggesting a role in enhancing hair follicle vascularization in androgenetic alopecia.